Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 11/2016

27.04.2016 | Original Article

Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer

verfasst von: Amir Sabet, Ina Binse, Hong Grafe, Samer Ezziddin, Rainer Görges, Thorsten D. Poeppel, Andreas Bockisch, Sandra J. Rosenbaum-Krumme

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nodal involvement is an independent risk factor of recurrence in papillary thyroid cancer (PTC). Neither the international guidelines nor the recently introduced ongoing risk adaptation concept consider the extent of initial surgical clearance of radioiodine sensitive lymph node metastases in their stratification systems. We investigated the prognostic relevance of incomplete initial surgical clearance in patients with purely lymphogeneous metastatic PTC (pN1 M0) despite successful radioiodine therapy. Accurate assessment of pre-ablative nodal status was attempted using PET/CT studies with both 124I-NaI and 18F-FDG along with high-resolution cervical ultrasound.

Methods

Sixty-five patients with histologically diagnosed lymph node metastases (pN1 M0) were retrospectively analyzed. Patients with iodine-negative lymph node metastases diagnosed by 18F-FDG PET/CT or distant metastases were excluded from the analysis. The association of disease recurrence with the pre-ablative nodal status, as well as other baseline characteristics, were examined applying nonparametric tests for independent samples and multiple regression analysis. Patients with persistent lymph node metastases in 124I-NaI PET/CT were further divided according to the additional presence or absence of FDG-uptake in 18F-FDG PET/CT. Survival analyses were performed using Kaplan–Meier curves and the Cox proportional hazards model for uni- and multivariate analyses to assess the influence of prognostic factors on progression free survival (PFS).

Results

Incomplete metastatic lymph node resection captured by 124I-NaI PET/CT (n = 33) was an independent risk factor for recurrence (61 % vs 25 %, p = 0.006) and shorter PFS (46 months vs not reached, HR 4.0 [95 %-CI, 1.7–9.2], p = 0.001). Ultrasound could detect lymph node metastases only in 19/33 patients (58 %). Among patients with positive nodal status, FDG-avidity of metastatic iodine positive lymph nodes worsened the outcome (16 vs 69 months, p = 0.047). From all other investigated factors including age, N-stage (N1a vs N1b), and T-Stage (T4 vs T1-3), only large tumor size (pT4) had a significant impact on PFS (HR 2.9 [95 %-CI, 1.3–6.4], p = 0.007).

Conclusions

Incomplete initial surgical clearance of lymph node metastases even after successful radioiodine therapy may increase the chances of recurrence and is an independent risk factor for impaired survival of patients with PTC. Pre-ablative (dual tracer PET/CT) imaging with 124I-Na and 18F provides a prognostic tool for these patients and may considerably complement the current risk stratification systems.
Literatur
3.
Zurück zum Zitat Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229–39.PubMed Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229–39.PubMed
4.
Zurück zum Zitat Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468–74. doi:10.1200/JCO.2012.42.4457.CrossRefPubMed Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468–74. doi:10.​1200/​JCO.​2012.​42.​4457.CrossRefPubMed
5.
Zurück zum Zitat Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg. 1992;164:671–6.CrossRefPubMed Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg. 1992;164:671–6.CrossRefPubMed
6.
Zurück zum Zitat Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case–control study. Cancer. 2006;106:524–31. doi:10.1002/cncr.21653.CrossRefPubMed Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case–control study. Cancer. 2006;106:524–31. doi:10.​1002/​cncr.​21653.CrossRefPubMed
7.
Zurück zum Zitat Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014;7:5393–403.PubMedPubMedCentral Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014;7:5393–403.PubMedPubMedCentral
8.
Zurück zum Zitat Dralle H, Musholt TJ, Schabram J, Steinmuller T, Frilling A, Simon D, et al. German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398:347–75. doi:10.1007/s00423-013-1057-6.CrossRefPubMed Dralle H, Musholt TJ, Schabram J, Steinmuller T, Frilling A, Simon D, et al. German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398:347–75. doi:10.​1007/​s00423-013-1057-6.CrossRefPubMed
9.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi:10.1089/thy.2015.0020.CrossRefPubMed Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi:10.​1089/​thy.​2015.​0020.CrossRefPubMed
10.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. doi:10.1089/thy.2009.0110.CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. doi:10.​1089/​thy.​2009.​0110.CrossRefPubMed
11.
Zurück zum Zitat Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:143–6. doi:10.1093/annonc/mdp156.PubMed Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:143–6. doi:10.​1093/​annonc/​mdp156.PubMed
14.
Zurück zum Zitat Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid: Off J Am Thyroid Assoc. 2010;20:1341–9. doi:10.1089/thy.2010.0178.CrossRef Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid: Off J Am Thyroid Assoc. 2010;20:1341–9. doi:10.​1089/​thy.​2010.​0178.CrossRef
15.
Zurück zum Zitat Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441–6. doi:10.1530/EJE-11-0466.CrossRefPubMed Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441–6. doi:10.​1530/​EJE-11-0466.CrossRefPubMed
16.
Zurück zum Zitat Cano-Palomares A, Castells I, Capel I, Bella MR, Barcons S, Serrano A, et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems. Int J Endocrinol. 2014;2014:591285. doi:10.1155/2014/591285.CrossRefPubMedPubMedCentral Cano-Palomares A, Castells I, Capel I, Bella MR, Barcons S, Serrano A, et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems. Int J Endocrinol. 2014;2014:591285. doi:10.​1155/​2014/​591285.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT. Eur J Nucl Med Mol Imaging. 2013;40:693–700. doi:10.1007/s00259-012-2331-5.CrossRefPubMed de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT. Eur J Nucl Med Mol Imaging. 2013;40:693–700. doi:10.​1007/​s00259-012-2331-5.CrossRefPubMed
18.
Zurück zum Zitat Jentzen W, Moldovan AS, Ruhlmann M, Gorges R, Bockisch A, Rosenbaum-Krumme S. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54:137–43. doi:10.3413/Nukmed-0711-14-12.CrossRefPubMed Jentzen W, Moldovan AS, Ruhlmann M, Gorges R, Bockisch A, Rosenbaum-Krumme S. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54:137–43. doi:10.​3413/​Nukmed-0711-14-12.CrossRefPubMed
19.
20.
Zurück zum Zitat Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759–65. doi:10.2967/jnumed.114.144089.CrossRefPubMed Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759–65. doi:10.​2967/​jnumed.​114.​144089.CrossRefPubMed
21.
Zurück zum Zitat Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147–59. doi:10.1159/000354537.CrossRefPubMedPubMedCentral Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147–59. doi:10.​1159/​000354537.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and number of lymph node metastases Are associated with compromised survival for patients younger than Age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–5. doi:10.1200/JCO.2014.59.8391.CrossRefPubMed Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and number of lymph node metastases Are associated with compromised survival for patients younger than Age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–5. doi:10.​1200/​JCO.​2014.​59.​8391.CrossRefPubMed
23.
Zurück zum Zitat Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014;21:277–83. doi:10.1245/s10434-013-3258-1.CrossRefPubMed Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014;21:277–83. doi:10.​1245/​s10434-013-3258-1.CrossRefPubMed
24.
Zurück zum Zitat Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013;168:219–25. doi:10.1530/EJE-12-0744.CrossRefPubMed Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013;168:219–25. doi:10.​1530/​EJE-12-0744.CrossRefPubMed
26.
Zurück zum Zitat Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634–40. doi:10.1002/lary.23371.CrossRefPubMed Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634–40. doi:10.​1002/​lary.​23371.CrossRefPubMed
27.
Zurück zum Zitat Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2187–94. doi:10.1210/jc.2010-0063.CrossRefPubMed Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2187–94. doi:10.​1210/​jc.​2010-0063.CrossRefPubMed
28.
Zurück zum Zitat Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid: Off J Am Thyroid Assoc. 2006;16:1229–42. doi:10.1089/thy.2006.16.1229.CrossRef Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid: Off J Am Thyroid Assoc. 2006;16:1229–42. doi:10.​1089/​thy.​2006.​16.​1229.CrossRef
29.
Zurück zum Zitat Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–9. doi:10.1530/eje.1.02014.CrossRefPubMed Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–9. doi:10.​1530/​eje.​1.​02014.CrossRefPubMed
31.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803. doi:10.1530/eje.1.02158.CrossRefPubMed Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803. doi:10.​1530/​eje.​1.​02158.CrossRefPubMed
32.
Zurück zum Zitat Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170:23–30. doi:10.1530/EJE-13-0524.CrossRefPubMed Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170:23–30. doi:10.​1530/​EJE-13-0524.CrossRefPubMed
33.
Zurück zum Zitat Lepoutre-Lussey C, Maddah D, Golmard JL, Russ G, Tissier F, Tresallet C, et al. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol. 2014;170:837–46. doi:10.1530/EJE-13-0888.CrossRefPubMed Lepoutre-Lussey C, Maddah D, Golmard JL, Russ G, Tissier F, Tresallet C, et al. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol. 2014;170:837–46. doi:10.​1530/​EJE-13-0888.CrossRefPubMed
34.
Zurück zum Zitat Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48–56. doi:10.1007/s00259-011-1773-5.CrossRefPubMed Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48–56. doi:10.​1007/​s00259-011-1773-5.CrossRefPubMed
35.
Zurück zum Zitat Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879–83. doi:10.1089/thy.2009.0430.CrossRefPubMed Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879–83. doi:10.​1089/​thy.​2009.​0430.CrossRefPubMed
37.
Zurück zum Zitat Haslerud T, Brauckhoff K, Reisaeter L, Kufner-Lein R, Heinecke A, Varhaug JE, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol. 2015. doi:10.1177/0284185115594645.PubMed Haslerud T, Brauckhoff K, Reisaeter L, Kufner-Lein R, Heinecke A, Varhaug JE, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol. 2015. doi:10.​1177/​0284185115594645​.PubMed
38.
Zurück zum Zitat Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–13. doi:10.1210/jcem.85.3.6458.PubMed Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–13. doi:10.​1210/​jcem.​85.​3.​6458.PubMed
39.
Zurück zum Zitat Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–52.CrossRefPubMed Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–52.CrossRefPubMed
40.
42.
Zurück zum Zitat Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL, et al. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative I whole-body scan results: a meta-analysis. Head Neck. 2014. doi:10.1002/hed.23881. Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL, et al. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative I whole-body scan results: a meta-analysis. Head Neck. 2014. doi:10.​1002/​hed.​23881.
Metadaten
Titel
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer
verfasst von
Amir Sabet
Ina Binse
Hong Grafe
Samer Ezziddin
Rainer Görges
Thorsten D. Poeppel
Andreas Bockisch
Sandra J. Rosenbaum-Krumme
Publikationsdatum
27.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3400-y

Weitere Artikel der Ausgabe 11/2016

European Journal of Nuclear Medicine and Molecular Imaging 11/2016 Zur Ausgabe